Literature DB >> 22183137

Anxiety and depression symptoms in arterial hypertension: the influence of antihypertensive treatment. the HUNT study, Norway.

Aslak Johansen1, Jostein Holmen, Robert Stewart, Ottar Bjerkeset.   

Abstract

Antihypertensive drugs have been suggested to modulate symptoms of depression and anxiety. It is disputed whether this is due to the hypertension per se, its treatment, or both. The aim of this study was to investigate these associations in a large population sample. 55,472 participants in the Nord-Trøndelag Health Study (HUNT 2, 1995-1997), Norway, who completed the Hospital Anxiety and Depression rating Scale, were divided into 3 groups according to their diastolic blood pressure and antihypertensive treatment status. A cut-off of ≥90 mmHg diastolic blood pressure was used to identify hypertensive status. Differences in anxiety and depression symptom levels in untreated and treated hypertensives (all treatments) versus the normotensive reference group were explained by differences in age and gender distribution in the three groups in this study. However, the receipt of two or more antihypertensive drugs was associated with depressive symptoms alone (OR = 1.40, 95% CI = 1.03-1.90), but not with symptoms of anxiety (OR = 1.14, 95% CI = 0.83-1.57) or mixed anxiety and depression (OR = 1.19, 95% CI = 0.82-1.72) in the fully adjusted model, compared to untreated hypertension. Antihypertensive monotherapy (all agents) nor any single antihypertensive drug class were associated with symptoms of depression, anxiety, or mixed anxiety and depression. There may be a positive association between multi antihypertensive drug use and symptoms of depression, whereas this was not found in persons with symptoms of anxiety or mixed anxiety and depression. This might reflect poor antihypertensive treatment adherence leading to polypharmacy, or other unfavorable health behaviors in people with symptoms of pure depression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22183137     DOI: 10.1007/s10654-011-9641-y

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  52 in total

1.  Cardiovascular drug prescriptions and risk of depression in diabetic patients.

Authors:  W Rathmann; B Haastert; J M Roseman; G Giani
Journal:  J Clin Epidemiol       Date:  1999-11       Impact factor: 6.437

2.  Treatment of recurrent unipolar major depression with captopril.

Authors:  L Germain; G Chouinard
Journal:  Biol Psychiatry       Date:  1988-03-15       Impact factor: 13.382

3.  Depressive symptoms in coronary artery disease patients after hypertension treatment.

Authors:  L Douglas Ried; Michael J Tueth; Michael D Taylor; Brian C Sauer; Larry M Lopez; Carl J Pepine
Journal:  Ann Pharmacother       Date:  2006-03-28       Impact factor: 3.154

4.  Case-control studies of cardiovascular medications as risk factors for clinically diagnosed depressive disorders in a hospitalized population.

Authors:  S B Patten; J V Williams; E J Love
Journal:  Can J Psychiatry       Date:  1996-09       Impact factor: 4.356

5.  Propranolol-induced depression: mechanism and management.

Authors:  G Oppenheim
Journal:  Aust N Z J Psychiatry       Date:  1983-12       Impact factor: 5.744

6.  Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial.

Authors:  P N Dannon; Y Sasson; S Hirschmann; I Iancu; L J Grunhaus; J Zohar
Journal:  Eur Neuropsychopharmacol       Date:  2000-05       Impact factor: 4.600

7.  Absence of association between depression and hypertension: results of a prospectively designed population-based study.

Authors:  M Wiehe; S C Fuchs; L B Moreira; R S Moraes; G M Pereira; M Gus; F D Fuchs
Journal:  J Hum Hypertens       Date:  2006-06       Impact factor: 3.012

8.  Help-seeking behaviour in patients with anxiety disorder and depression.

Authors:  A Roness; A Mykletun; A A Dahl
Journal:  Acta Psychiatr Scand       Date:  2005-01       Impact factor: 6.392

Review 9.  Antihypertensive drug interactions.

Authors:  Barry L Carter
Journal:  Drugs Today (Barc)       Date:  2005-01       Impact factor: 2.245

Review 10.  [Post-stroke depression (I). Epidemiology, diagnostic criteria and risk factors].

Authors:  F J Carod-Artal
Journal:  Rev Neurol       Date:  2006 Feb 1-15       Impact factor: 0.870

View more
  13 in total

1.  The Rotterdam Study: 2014 objectives and design update.

Authors:  Albert Hofman; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2013-11-21       Impact factor: 8.082

2.  Symptoms of anxiety and depression and risk of heart failure: the HUNT Study.

Authors:  Lise T Gustad; Lars E Laugsand; Imre Janszky; Håvard Dalen; Ottar Bjerkeset
Journal:  Eur J Heart Fail       Date:  2014-07-12       Impact factor: 15.534

3.  Monotherapy With Major Antihypertensive Drug Classes and Risk of Hospital Admissions for Mood Disorders.

Authors:  Angela H Boal; Daniel J Smith; Linsay McCallum; Scott Muir; Rhian M Touyz; Anna F Dominiczak; Sandosh Padmanabhan
Journal:  Hypertension       Date:  2016-10-10       Impact factor: 10.190

4.  Cardiac function associated with previous, current and repeated depression and anxiety symptoms in a healthy population: the HUNT study.

Authors:  L T Gustad; O Bjerkeset; L B Strand; I Janszky; Ø Salvesen; H Dalen
Journal:  Open Heart       Date:  2016-02-15

5.  Prevalence and predictive nomogram of depression among hypertensive patients in primary care: A cross-sectional study in less developed Northwest China.

Authors:  Lin Wang; Nanfang Li; Mulalibieke Heizhati; Mei Li; Fengyu Pan; Zhikang Yang; Zhongrong Wang; Reyila Abudereyimu
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

6.  Development of the Chinese family support scale in a sample of Chinese patients with hypertension.

Authors:  Gang Li; Huanhuan Hu; Zhong Dong; Takashi Arao
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

7.  Risk of developing depressive disorders following rheumatoid arthritis: a nationwide population-based study.

Authors:  Shu-Li Wang; Cheng-Ho Chang; Li-Yu Hu; Shih-Jen Tsai; Albert C Yang; Zi-Hong You
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

Review 8.  The renin-angiotensin system: a possible new target for depression.

Authors:  João Vian; Círia Pereira; Victor Chavarria; Cristiano Köhler; Brendon Stubbs; João Quevedo; Sung-Wan Kim; André F Carvalho; Michael Berk; Brisa S Fernandes
Journal:  BMC Med       Date:  2017-08-01       Impact factor: 8.775

9.  Chart review of patients receiving valsartan-amlodipine single-pill combination versus valsartan and amlodipine combination for blood pressure goal achievement and effects on the Hamilton anxiety rating/Hamilton depression rating scales.

Authors:  Gang Yin; Yuefan Li; Wenjie Xu; Na Han
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

Review 10.  Depression as an Immunometabolic Disorder: Exploring Shared Pharmacotherapeutics with Cardiovascular Disease.

Authors:  Mervin Chávez-Castillo; Manuel Nava; Ángel Ortega; Milagros Rojas; Victoria Núñez; Juan Salazar; Valmore Bermúdez; Joselyn Rojas-Quintero
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.